Form 4: Tarsus Pharmaceuticals Executive Receives Stock Grant
Insider Transaction (Form 4)
Neera Clase, Chief Commercial Officer of Tarsus Pharmaceuticals, Inc., reported multiple transactions in common stock on November 3, 2026.
Summary
- Grant/award: acquired 10,587 Stock Option (right to buy) on November 3, 2026; holds 10,587 after (Direct).
- Grant/award: acquired 6,678 Restricted Stock Units on November 3, 2026; holds 6,678 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Neera Clase — Officer (Chief Commercial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-11-03 | Grant/award | Stock Option (right to buy) | 10,587 | — | — | 10,587 |
| 2026-11-03 | Grant/award | Restricted Stock Units | 6,678 | — | — | 6,678 |
Key Dates
| Date | Description |
|---|---|
| 2026-11-03 | Grant/award (10,587 shares) |
| 2026-11-03 | Grant/award (6,678 shares) |
Keywords
insider transaction, Form 4, TARS, Tarsus Pharmaceuticals, Inc., neutral, Neera Clase
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.